These findings imply that sclerostin, which is secreted locally by tumor cells, has a protective role in the progression of prostate cancer through the Wnt-signaling pathway inhibition, and elevated serum sclerostin levels reflect the increased activity of osteoblasts and osteocytes at the osteoblastic lesions induced by prostate cancer. This evidence concerns the gene SOST and prostate carcinoma.